Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
303 questions in 64 reviews · Hepato-Biliary
current versionsNo studies 303 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Interventions · people undergoing liver transplantation Maintenance immunosuppression for adults undergoing liver transplantation: a network meta‐analysis (2017) · Cochrane | no estimate extracted | NR | No studies |
Thiazolidinediones vs no intervention Health‐related quality of life · participants with non‐alcohol related fatty liver disease (NAFLD) Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Health‐related quality of life · participants with non‐alcohol related fatty liver disease (NAFLD) Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) (2017) · Cochrane | no estimate extracted | NR | No studies |
Bile acids vs no intervention Health‐related quality of life · participants with non‐alcohol related fatty liver disease (NAFLD) Pharmacological interventions for non‐alcohol related fatty liver disease (NAFLD) (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon vs no intervention Progression to fulminant HBV infection · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon vs no intervention Adverse events (number of events) · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Lamivudine vs no intervention Progression to fulminant HBV infection · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Lamivudine vs no intervention Health‐related quality of life (1 week) · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon vs no intervention Short‐term mortality · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon vs no intervention Progression to chronic HBV infection · people with acute HBV infection Pharmacological interventions for acute hepatitis B infection (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin plus glucagon vs no intervention Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin plus glucagon vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Insulin plus glucagon vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Early mortality (mortality up to 90 days) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (proportion) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Serious adverse events (number) · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Health‐related quality of life · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Serious adverse events (number) · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Health‐related quality of life · participants with severe alcoholic hepatitis Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Anabolic steroids vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Antioxidants vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Glucocorticosteroids vs no intervention Health‐related quality of life · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Early mortality (mortality up to 90 days) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (proportion) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Serious adverse events (number) · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Propylthiouracil vs no intervention Health‐related quality of life · alcohol‐related disorders (others) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Pentoxifylline vs no intervention Serious adverse events (number) · participants with alcoholic hepatitis (all severity) Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) (2017) · Cochrane | no estimate extracted | NR | No studies |
Erythrocytapheresis vs phlebotomy Health‐related quality of life beyond one year · people with hereditary haemochromatosis Interventions for hereditary haemochromatosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Colchicine vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Serious adverse events (proportion) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Serious adverse events (number of events) · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |
Ciclosporin vs no intervention Health‐related quality of life · people with primary biliary cholangitis Pharmacological interventions for primary biliary cholangitis (2017) · Cochrane | no estimate extracted | NR | No studies |